Enteris BioPharma

Enteris BioPharma, Inc., a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), offers comprehensive integrated CMC and CDMO service support, including pre-formulation, proprietary and non-proprietary formulation development, analytical research and development, quality assurance, and cGMP clinical and commercial manufacturing of drug dosage forms. Enteris BioPharma is advancing an innovative internal product pipeline focused on the oral tablet reformulation of pharmaceutical products to address significant therapeutic opportunities lacking oral administration options. Enteris BioPharma’s most advanced internal candidate product, Ovarest® (oral leuprolide tablets), is an oral peptide being developed for the treatment of endocrine disorders. Tobrate™ (oral tobramycin tablets) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infections (uUTI).